#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Antisynthetase syndrome Multiple system atrophy Hereditary ataxia Chronic granulomatous disease Mycobacterium abscessus infection Mitochondrial DNA depletion Nasopharyngeal cancer Conjunctivitis allergic Chemical burn Synovial sarcoma metastatic Biliary cancer metastatic Diffuse large B-cell lymphoma Prolymphocytic leukaemia Liposarcoma Rhabdomyosarcoma recurrent More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Trials in Disease Gastrointestinal stromal tumour – Life with Disease Angiosarcoma metastatic Arterial tortuosity syndrome – Treatment Prolymphocytic leukaemia – Life with Disease Richter’s syndrome – Basic Information Hereditary ataxia – Treatment Adrenocortical carcinoma Chronic granulomatous disease – Treatment Marginal zone lymphoma refractory More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VELPATASVIR OBI-821 Tacrolimus Omp65 Tirbanibulin Bcmacp03 GSKVX000000030810 RUBIDIUM CHLORIDE Tenofovir Disoproxil Fumarate Dipyridamole Prilocaine Obinutuzumab Sasanlimab Dacarbazine Buprenorphine Latozinemab Anhydrous Cholestyramine Frexalimab Sarilumab Bemcentinib More therapies…

    Learn about Your Condition

    Asplenia Perinatal depression Bronchopulmonary dysplasia Atrophic vulvovaginitis Breast neoplasm Urticaria Asthma Oesophageal atresia Pyoderma gangrenosum Aortic stenosis Synovial sarcoma metastatic Endometrial stromal sarcoma Meningioma malignant Rhabdomyosarcoma Metastasis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Dostarlimab
    • Paclitaxel
    France Italy Romania Spain

  • Study on Dostarlimab to Prevent Second Cancer in Patients Cured from Primary Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    France

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Nivolumab
    • Sunitinib
    Bulgaria Croatia Czechia Denmark Finland France +8

  • Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Xaluritamig
    Austria Belgium Denmark France Germany Greece +5

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • A Study of Saruparib for Patients with Metastatic Pancreatic Cancer with Homologous Repair Deficiency as First Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • Saruparib
    France

  • Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • BMS-986365
    • Abiraterone
    • Docetaxel
    Austria Czechia Denmark France Germany Ireland +6

  • Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    4 1 1
    Investigated Drugs:
    • HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4
    • Pembrolizumab
    Belgium Bulgaria France Italy Poland Romania +1

  • Study of AGuIX Nanoparticles and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Glioblastoma
    France
Previous Page
1 … 9 10 11 12 13 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!